Skinbiotherapeutics Share Discussion Threads

[bobalot] 24/11/2017 14:34

Another fanatic just arrived from OPTI....SBTX IS A FAR BETTER AND SAFER INVESTMENT for PI's imo


DREAM ON ABOUT FREE SHARES FROM OPTI ON A 1:1 RATIO.....fantasy, pie in the sky.

[loungeact] 24/11/2017 14:34

I wonder if Bobalot understood all that, wait...let me translate...“WHAT IT MEANS FOR SHAREHOLDERS, TYPICALLY THEY RETAIN THEIR POSITION IN OPTIBIOTIX, BUT THEY ALSO GAIN A PROPORTIONAL POSITION IN THE NEW LISTED COMPANY. SO FOR A SHAREHOLDER POINT OF VIEW, IT’S A WAY OF GREATLY INCREASING THEIR SHAREHOLDING.” STEPHEN O’HARA - CEO OF OPTIBIOTIX.

[slartybartfaster] 24/11/2017 14:32

Unfortunately bob dont understand certain aspects of the markets, me included. I wouldnt accuse someone trying to help be of being a 'unreliable and a con artist' instead of being grateful for the help.

[riskybusiness1] 24/11/2017 14:14

SOH was the mastermind behind the Skinbio acquisition and IPO listing he will do what's best for Opti shareholders being the largest shareholder with a 20% holding including shares held under option.Bob trying to antagonise Opti holders is ridiculously stupid considering how SKINBIO came in to existence.

[loungeact] 24/11/2017 13:48

This a great video from last year, where SOH talks about listing Skinbiotheraputics - -- “What it means for shareholders, typically they retain their position in Optibiotix, but they also gain a proportional position in the new listed company. So for a shareholder point of view, it’s a way of greatly increasing their shareholding.” Stephen O’Hara - CEO of Optibiotix. -- It's a shame for anyone that sold their OPTI shares. LOLOLOL

[bobalot] 24/11/2017 13:23

SkinBiotherapeutics readying for cosmetic cream launch after safety test success

SkinBiotix recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours

First product will be skin care cream

SkinBioTherapeutics PLC (LON:SBTX) expects a study in people of a cosmetic skin care cream next year to be the start of ‘serious’; commercialisation talks.

Tentative discussions have already begun, Cath O’Neill, the skin microbiome specialist’s chief executive told Proactive Investors, but human data is crucial to the process.  

“Human data is gold dust. The results of the study will spark a major value inflexion point from which we can start serious conversations about commercialisation.”

SkinBiotix, the company's microbiome platform, will be tested in a cosmteic consumer efficacy study, a far less demanding process than clinical trials.
Around sixty patients will be involved in the study for a month and if successful, it will be allowed on sale almost immediately.

Work on the formulation of the skin cream has also started, O’Neill said, adding this was another crucial part of the product development process.

SkinBiotix recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours and now just has two more safety tests to clear before the human efficacy study can begin.

SkinBioTherapeutics presented data recently at a microbiome symposium sponsored by Wellcome Trust that was well received, but the human trial will be a major step forward, she added.

“Once the results [from the human study] are in we are good to go.”
SkinBiotix might be either an ingredient in someone else’s product or a brand in its own right.

O’Neill was talking to Proactive after being named among the top 50 female movers and shakers in the BioBusiness 2017 report.

She said was delighted to receive the award especially as SkinbioTherapeutics was listed in the great science category.

“SkinBioTherapeutics is founded on very robust science and is proud of its scientific heritage.”

The company is working on three applications for its microbiome-based products: cosmetics; an anti-infective and an eczema treatment.
Shares rose 1% to 10.3p.

[bobalot] 24/11/2017 13:11

Here is a recap of some recent SBTX news.

SkinBiotherapeutics readying for cosmetic cream launch after safety test success


SkinBiotix recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours

First product will be skin care cream

SkinBioTherapeutics PLC (LON:SBTX) expects a study in people of a cosmetic skin care cream next year to be the start of ‘serious’; commercialisation talks.
Tentative discussions have already begun, Cath O’Neill, the skin microbiome specialist’s chief executive told Proactive Investors, but human data is crucial to the process.  

“Human data is gold dust. The results of the study will spark a major value inflexion point from which we can start serious conversations about commercialisation.”

SkinBiotix, the company's microbiome platform, will be tested in a cosmteic consumer efficacy study, a far less demanding process than clinical trials.

Around sixty patients will be involved in the study for a month and if successful, it will be allowed on sale almost immediately.

Work on the formulation of the skin cream has also started, O’Neill said, adding this was another crucial part of the product development process.

SkinBiotix recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours and now just has two more safety tests to clear before the human efficacy study can begin.

SkinBioTherapeutics presented data recently at a microbiome symposium sponsored by Wellcome Trust that was well received, but the human trial will be a major step forward, she added.

“Once the results [from the human study] are in we are good to go.”
SkinBiotix might be either an ingredient in someone else’s product or a brand in its own right.

O’Neill was talking to Proactive after being named among the top 50 female movers and shakers in the BioBusiness 2017 report.

She said was delighted to receive the award especially as SkinbioTherapeutics was listed in the great science category.

“SkinBioTherapeutics is founded on very robust science and is proud of its scientific heritage.”

The company is working on three applications for its microbiome-based products: cosmetics; an anti-infective and an eczema treatment.
Shares rose 1% to 10.3p.

[bobalot] 24/11/2017 13:09

It is pleasing to see the OPTI FANATICS are busy on the other thread today...they are still hoping for a 30% rise --- blinded by hype and fake intel....lol

[slartybartfaster] 23/11/2017 19:18

The overwhelming votes clearly show bobalot-losttheplot has lost the board, the lurkers have come out to vote and it is a land slide. Im left wondering how many have the idiot filtered now. The liars campaign has backfired on you bobalot-losttheplot.

[bobalot] 23/11/2017 18:46

People like you will never learn --- blinded by hype...lol

[bobalot] 23/11/2017 18:28

Except they don't own the business anymore as a wholly owned subsidiary --- they cashed out in a debt for equity swap and now only own 41% of the company -- at least 50-52% IS NEEDED to have a controlling interest. Despite what some posters are touting.

[pglancy] 23/11/2017 17:30

Optibiotix should be listed in the Bionow investment deal of the year awards for turning 560k into 12m in 12 months and still have 5m on the books waiting to pay out as a special divi. Just a thought.

[bobalot] 23/11/2017 16:26

SkinBioTherapeutics Retweeted Bionow

SkinBioTherapeutics shortlisted for the Bionow investment deal of the year awards.

SkinBioTherapeutics added,


Bionow‏ @Bionow
Follow @Bionow

More
Bionow awards shortlists announced! Bionow Investment Deal of the Year Award (Sponsored by @QIAGENscience) shortlist @ADCBIO @Acceleris @Microbiosensor @SkinBioT Sky Medical Technology #bionowawards17 hxxp://ow.ly/QKfx30gJcQw


SKINBIO MIGHT WIN AN AWARD SOON

[bobalot] 23/11/2017 15:56

you people really take the biscuit, SBTX is not a subsidiary....more looney tunes.

[pglancy] 23/11/2017 15:49

Try counting the votes. The email confirms what everyone agrees with, only you cant see it.

[bobalot] 23/11/2017 15:42

Try reading the email I got from SBTX...they spell out the relationship between the two businesses irrespective of what other posters prefer to believe. That is their reality that they want others to follow.

I would not touch OPTI with a barge pole as it is on a path to just being a holding company for its cashed up spin offs. I understand all the business arrangements and clearly a few posters prefer their own skewed version to serve their motives.

Here is a copy of the SBTX email from the financial director...believe what he says and nothing else as being verbatim.

Thank you for your mail which Cath forwarded on. Your understanding is correct, Opti own 41% of the shares in SBTX which is below the 50% level required to be deemed a subsidiary. Technically Opti’s investment in SBTX is defined as an ‘associate undertaking’ and it carries its holding in SBTX as an investment on its balance sheet.
 
From a practical point of view Opti & SBTX are two separate and independent companies with separate management teams and boards. As you are probably aware, Stephen O’Hara (CEO of Opti) sits on the board of SBTX as an NED. All other directors at SBTX are independent of and have no involvement with Opti.  
 
What Opti may or may not do with its holding in SBTX in the future is not something we’re in a position to comment on.
 
I hope this is of some assistance.
 
Kind regards
 
Doug Quinn
CFO
SkinBioTherapeutics plc

[bobalot] 23/11/2017 13:43

elrico 23 Nov '17 - 13:33 - 936 of 936    0   0 (Filtered)

BYE, BYE...I STILL DON'T BELIEVE YOU...SO I WON'T BE READING YOUR POSTS.

And you are now in denial.

[elrico] 23/11/2017 13:33

Peeps - can we leave my name out of this debate now, please. It is patently obvious Bobalot is very green, nieve and now we can now see he cannot to be trusted to be honest in debate. He remains filtered because he adds nothing other than volume of useless traffic to this thread.

I gather I'm some sort of deceiver, a con artist and have my facts wrong. Be very careful Bob, one poster that used the "ripelrico" pseudonym has had his ADVFN account closed as well as his own, after he posted falsehoods about me. And yes, he had to pay my legal fee 1x letter to ADVFN.

For the record: SBTX is no longer a subsidiary of OPTI, SBTX is a separate legal entity of its own as a PLC. I never suggested SBTX is a subsidiary, had I done so I would have been wrong and would, once corrected would have been man enough to stand corrected, as I have been previously.

Ref controlling interest: OPTI could use its 41.9% shareholding to influence at a AGM. They don't currently have a controlling interest, but a majority holding, significant enough to influence over say anything Seneca wanted to the direction of SBTX should it have a need - (purely as an example).

SOH does not hold any SBTX shares that I am aware of, but you point (PG) is a valid one.

[slartybartfaster] 23/11/2017 12:58

Spot on PG. Someuwin please sensor the lies. You usually do.

[pglancy] 23/11/2017 12:27

How stupid can you be? I have looked through elrico posts and i cannot agree with you. Sure he mentions Sbtx as subsidiary before it was spun out, he is right he even gave you the definition. You chose to spin it another way. He is also correct when he said opti have a controlling interest in the strict legal terms. See link

Definition of controlling shareholder
LR 6.1.2AR16/05/2014
A "controlling shareholder" means any person who exercises or controls on their own or together with any person with whom they are acting in concert, 30% or more of the votes able to be cast on all or substantially all matters at general meetings of the company.

Also you could add soh share to that if he chose to hammer home control but that would be hostile and i dont think soh is the type of ned that would do thiss.

You need to be careful making defamatory comments about a person we all know the true intensity of, you cannot say you are committing libelous comments to a username when you know his real name and it is in the public domain. Im surprised someuwin has allowed to to posts lies as often as you have he is usually very good at sensoring liars. He should do the same with you or risk this bb being trashed.